

PHILIP LEVY, M.D.
CURRICULUM VITAE

PHOENIX ENDOCRINOLOGY CLINIC, LTD
1300 N. 12TH Street, Suite 600
PHOENIX, AZ 85006

EDUCATION:

1952 B.S. University of Pittsburgh, Magna Cum Laude
1956 M.D. University of Pittsburgh School of Medicine;
Alpha Omega Alpha
1956-1957 Rotating Internship; Michael Reese Hospital, Chicago, IL
1957-1958 Basic Science Fellow in Metabolism and Endocrinology;
Michael Reese Hospital, Chicago, IL
1958-1960 Resident in Internal Medicine; Michael Reese Hospital,
Chicago, IL
1959-1960 Chief Resident, Internal Medicine; Michael Reese Hospital,
Chicago, IL
1960-1961 Fellow in Endocrinology and Metabolism; Michael Reese
Hospital, Chicago, IL
1960-1961 Clinical Instructor in Medicine; Chicago Medical School,
Chicago, IL
1961-1962 Research Fellow, American Diabetes Association; Guy's
Hospital Medical School, London, England
1962-present Clinical Practice of Endocrinology
Phoenix, AZ
1985-1995 Senior Clinical Lecturer in Internal Medicine; University of
Arizona School of Medicine
1995-present Clinical Professor of Medicine; University of Arizona
College of Medicine

CURRENT EMPLOYMENT

1970-present Phoenix Endocrinology Clinic, LTD
Phoenix, AZ

ORGANIZATIONS AND COMMITTEES:

Chairman, Department of Internal Medicine, Good Samaritan Hospital, Phoenix, AZ;
1976-1980
Chairman, Section of Endocrinology and Metabolism, Good Samaritan Hospital,
Phoenix, AZ; 1966-present

Chairman, Section of Endocrinology and Metabolism, St. Joseph's Hospital,
Phoenix, AZ; 1966-1972
President Arizona Diabetes Association; 1973-1975

Member, Board of Directors, Arizona Diabetes Association; 1971-present

Member, Professional Education Committee, American Diabetes Association; 1979-1981

Member, Public Education Committee, American Diabetes Association; 1982-1983

Member, Governmental Relations Committee, American Diabetes Association; 1983-
1985

Member, Board of Directors, American Diabetes Association; 1981-1984

Member, National Nominating Committee, American Diabetes Association; 1984-1986

Chairman, Task Force on Financing Quality Health Care, American Diabetes
Association; 1987-1989

Member, National Recognition Committee, American Diabetes Association; 1987-1989

Member, Professional Committee, Arizona Blue Shield; 1975-1986

Member, Board of Directors, Arizona Medical Association; 1979-1987

Member, Medical Education Committee, Arizona Medical Association; 1985-present

Alternate Delegate, American Medical Association; 1987-1990

Member, Medical Advisory Board, Arizona Division of Motor Vehicles; 1987-present

Secretary-Treasurer, Medical Staff, Good Samaritan Regional Medical Center, Phoenix,
AZ; 1979-1987

Vice Chief of Staff, Good Samaritan Regional Medical Center, Phoenix, AZ; 1987-1989

Chief of Staff, Good Samaritan Regional Medical Center 1989-1991

Past Chief of Staff, Good Samaritan Regional Medical Center; 1991-1993

Member, Board of Directors, Samaritan Health Services; 1989-1991

Member, Editorial Board of Diabetes Forecast; 1984-1987

Member, Professional Advisory Panel, American Diabetes Association; 1990-1992

Member, Editorial Board, Samaritan Medicine; 1983-1987

Editor In Chief, Diabetes Forecast; 1989-1994

Member, Clinical Initiatives Committee of the Endocrine Society; 1992-1998

Program Chairman, AACE Annual Meeting, Philadelphia, PA; April 1997

Program Chairman, AACE Annual Meeting April 1999- San Diego

Member, Professional Practice Committee, American Diabetes Association; 1996-1998

Member, Editorial Board, Clinical Diabetes; 1997-present

Member, The Endocrine Society, American College of Physicians, American Diabetes Association, Society of Nuclear Medicine, American Association of Clinical Endocrinology

Fellow, American College of Endocrinology

Member, Board of Directors AACE 1998-present

Member, AMAP Federation Advisory Committee 1998-present

Yank D. Coble Distinguished Service Award presented for Clinician of the Year by AACE

May, 2000

Life Member, National Registry of Who's Who

Consultant, Joslin Clinic 2002

Vice President, American College of Endocrinology 2002-2003

President, American College of Endocrinology 2003-2004

Editorial Board of Clinical Endocrinology-present

Editorial Board of Endocrine Today-present

BOARD CERTIFICATION

Internal Medicine, 1963

Endocrinology and Metabolism, 1972

Nuclear Medicine, 1976

CLINICAL RESEARCH STUDIES

1. Double-Blind comparison of Tolazamide and Glyburide in the management of NIDDM
2. Open label assessment of Diabinese and generic Chlorpropamide in patients with NIDDM
3. The use of Prazosin in patients with NIDDM and mild essential hypertension
4. A transfer study from pork and mixed beef-pork Lente insulin to Humulin Lente
5. Human Proinsulin versus biosynthetic Human insulin in NIDDM and IDDM
6. A comparison of Novopen and conventional syringes for administration of an intensive insulin regimen in patients with IDDM
7. A comparison of Novolin Pen and conventional syringes in the treatment of NIDDM
8. Tolrestat Retinopathy Prevention study
9. Evaluation of HOE-490 for treatment of NIDDM
10. The use of Aminoguanidine in prevention of diabetic kidney disease
11. Amylin 137-111- Thirteen week, multicenter, double-blind, parallel group, placebo controlled and AC137 dose ranging study to evaluate glycated hemoglobin and plasma glucose profiles in patients with Type 2 diabetes mellitus
12. Amylin 137-111E- A long term, multicenter, open dated, extension study to evaluate the tolerability and efficacy of Pramlintide (AC137) in patients completing Amylin protocol 137-111
13. Amylin 137-116- A long term, multicenter study to evaluate the tolerability of Pramlintide (AC137) in patients with Type 1 diabetes
14. Venlofaxine 0600B-215-65- A double-blind placebo controlled, randomized study of Venlofaxine extended release capsules for the treatment of chronic pain associated with diabetic neuropathy
15. Pimagedine AGPR002- A Placebo controlled safety and efficiency study of Aminoguanidine in diabetic patients with overt diabetic nephropathy
16. Lys-Pro Insulin-Crossover study in Type 2 diabetes mellitus
17. RPR NID525-209- A double-blinded, placebo controlled, randomized, multiple-dose study of the effects of NID525 and Triglitazone in Non-Insulin Dependent Diabetic Patients.
18. PPA20005- A Multicenter, Double-blind, Placebo-controlled, Parallel group, Dose ranging (0.25 to 10mg) Clinical evaluation of Oral G1262570X as a Monotherapy for 12 weeks duration in patients with Type 2 Diabetes Mellitus
19. 799- A Multicenter, Double blind, Placebo-Group Study of the Effects of Oral Zopolrestat in subjects with Peripheral Symmetrical Diabetic Polyneuropathy
20. CTN 97-0339-025- An Open label, Multicenter, longterm safety and efficacy of Genotropin replacement in adults with growth hormone deficiency in either adult or childhood onset
21. B9R-MC-GDEE (HypoCCS)- An Open-label, Multicenter drug surveillance study which will collect information on the clinical day to day management of adult hypopituitary, somatotropin deficient patients
22. EXO-04_{R2} – A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Two-Year Study of the Effect of the Anti-Glycation Agent, EXO-226 on Renal Dysfunction in Two Strata of Albuminuric Diabetic Patients
23. SPRI P00475 – A Phase III Double-Blind Efficacy and Safety Study of One Dose of

- SCH58235 (10mg) Compared to Placebo in Subjects with Primary Hypercholesterolemia
24. Hoechst Marion Roussel – Protocol HOE901/4002 – Target Glycemic control and the Incidence of Symptomatic Nocturnal Hypoglycemia in Insulin Naïve Subjects with Type 2 Diabetes on Oral Hypoglycemic Agent(s) and Treated with Insulin Glargine or NPH Human Insulin
 25. Genzyme Corporation - Protocol THYR-006-99 – A Multi-Center, open-Label, Single-Arm Phase IV Trial Evaluation the Diagnostic Utility of Thyrogen® (Thyrotropin alfa for Injection)-Stimulated Thyroglobulin Testing for the Surveillance of Patients with Treated Papillary or Follicular Thyroid Carcinoma at Risk for Recurrence
 26. SmithKline Beecham – Protocol number: BRL-049653C/150 - Rosiglitazone Evaluation: Advancing Current Treatment of Type 2 Diabetes (REACT2 Diabetes™)
 27. Purdue Pharma -- Protocol No. KD98-0603: A Randomized, Double-Blind, Placebo-Controlled, Dose Titration Study of V20001 in Type 2 Diabetic Patients Treated Only with Diet and/or Exercise.
 28. Aventis Pharmaceuticals – Protocol No. HOE901/4014: Lantus® (Insulin Glargine) vs. Avandia® (Rosiglitazone) as Add-On Therapy in Patients Failing Sulfonylurea and Glucophage® (Metformin) Combination Treatment: A Randomized, Open, Parallel Study
 29. Novartis – Protocol No. CDJN608 US01: A Multicenter, Open-Label, 12 Week Study to Evaluate the Glycemic Control Achieved with Starlix® 120 mg in Subjects with Type 2 Diabetes Mellitus in a Practice - Based Setting.
 30. Bristol-Myers Squibb – Protocol No. CV137-120: Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE)
 31. Aventis Pharmaceuticals – Protocol No. HMR1964/3002: A 26 Week, Multinational, Multicenter, Controlled, Open, 1:1 Randomized, Parallel Clinical Trial Comparing HMR1964 With Regular Human Insulin Injected Subcutaneously in Subjects With Type 2 Diabetes Mellitus Also Using NPH Insulin, and Which Will Lead into a Comparative 26- Week Extension Study (HMR1964/3012)
 32. Aventis Pharmaceuticals – Protocol No. HMR1964/3004: A 12 Week, Multinational, Multicenter, Controlled, Open, 1:1:1 Randomized, Parallel Clinical Trial to Assess Noninferiority Between Pre- and Post- Meal Administration of HMR1964 and Pre-Meal Regular Human Insulin in Subjects with Type 1 Diabetes Mellitus Receiving Insulin Glargine as the Basal Insulin Therapy.
 33. Novo Nordisk Pharmaceuticals-Protocol No. BIAsp-2174: A Phase IV Muticenter, Open Label Trial using NovoLog Mix 70/30 (Biphasic Insulin Aspart 70/30) Titrate Target: An Observational Study of the Efficacy of NovoLog 70/30 in Patients with Type 2 Diabetics Not Achieving Glycemic Targets on OADs with/without Once Daily Basil Insulin Therapy
 34. Novo Nordisk Pharmaceuticals- Protocol No .BIAsp-2186: A Muticenter, Open Label, Randomized Trial to Compare the Efficacy and Safety of NovoLog Mix 70/30 BID in Combination with Metformin and Pioglitazone Alone in Insulin Naïve Subject with Type 2 Diabetes
 35. ANA-2190- An Open-Label, Multi Center, Clinical Trial: External Continuous Subcutaneous Infusion of Insulin using Insulin Aspart (NovoLog) in Subject with

- Type 1 and Insulin Requiring Type 2 Diabetes
36. Sonofi Aventis Pharmaceuticals-Protocol No. HMR1964A/3508: Lantus plus Apedria MDI versus Premix insulin treatment in subject with diabetes mellitus (type 1 or 2) evaluating differences in patient reported outcomes. A randomization, multicenter, cross over study.
 37. Pfizer Pharmaceuticals-Protocol No. A2171066: A US randomized questionnaire-based trial assessing the impact of the availability of inhaled insulin an therapeutic choice in patients with suboptimally controlled type 2 diabetes.
 38. Amylin Pharmaceuticals-Protocol No. 137-156: A randomized, double, placebo-controlled, multicenter study evaluating the efficacy and safety of adding Symlin to Lantus in subjects with type 2 diabetes who are not achieving glycemic targets.
 39. PfizerPharmaceuticals-Protocol No. A2171093: A Phase 3B, Randomized, Open-Label, Paralle Group Mulicenter Trial Assessing the Efficacy of Exubera vs. Lispro Introduced into a Lantus Based Regimen in Suboptimally Controlled Patients with Type 2 Diabetes Mellitus.
 40. Novartis Pharmaceuticals-Protocol No. CLAF237A23119: A Multi-center, Randomized, Open-Label, Active Controlled, Parallel Arm Study to Compare the Efficacy of 12 Weeks of Treatment with Vildagliptin 100mg, qd to Thiazolidinedione (TZD) as Add-On Theraphy in Patients with type 2 Diabetes Inadequately Controlled with Metformin Monotherapy

BOOK REVIEWS AND AUTHORSHIPS

American Medical Association Guides to the Evaluation of Permanent Impairment;1993

Demeter, Anderson and Smith. Disability Evaluation; 1996 MKSAP in Endocrinology; 1995

American Diabetes Association Complete Guide to Diabetes; 1996

Time Life. The Medical Advisor; 1996